With this, Venus Remedies has secured 525 marketing approvals for its oneology products across 76 countries.

The $420 billion pharmaceutical market of the Philippines presents immense opportunities for the company to expand its operations in the Asia-Pacific region in general and Southeast Asia in particular. Venus Remedies has already submitted dossiers to the Health Ministry of the Philippines government for another 45 marketing authorisations, and most of these pending approvals are for oncology products.

Venus Remedies has also secured marketing approval from Myanmar for the chemotherapy drug oxaliplatin.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed-dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation. The company's consolidated net profit tumbled 82.9% to Rs 1.18 crore on 33.5% decline in net sales to Rs 95.15 crore in Q1 FY24 over Q1 FY23.